Enalapril ODT - Ethicare GmbH

Drug Profile

Enalapril ODT - Ethicare GmbH

Latest Information Update: 03 Dec 2015

Price : $50

At a glance

  • Originator Ethicare GmbH
  • Class Antihypertensives; Heart failure therapies; Small molecules
  • Mechanism of Action ACE inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Heart failure

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 30 Nov 2015 Ethicare initiates enrolment in a phase III follow up trial in Heart failure (In infants, In children) in Austria and Hungary (PO) (EudraCT2015-002397-21)
  • 30 Nov 2015 Phase-III clinical trials in Heart failure (In neonates, In infants, In Children) in Austria and Hungary (PO) (EudraCT2015-002396-18)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top